Centralized procurement to promote insulin and Chinese patent medicines to promote drug bidding in one place and publish new "retaliatory" regulations

The time of 2021 is always in a hurry, and in a blink of an eye it comes to October, a national celebration
.
Looking back on September, the blockbuster medical policy was announced in full swing
.
First of all, at the beginning of this month, the National Health Commission issued a notice on the "Regulations for the National Key Monitoring and Reasonable Use of Drugs Catalogue Adjustment", and six types of drugs were listed in the "Key Monitoring Drug Catalogue
.
" This six drugs comprising: an auxiliary drug, an antineoplastic, antimicrobial agents, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs
.
It is worth noting that the above-mentioned 6 categories do not include proprietary Chinese medicines.
Looking back at the first round of the first-round list of 20 key monitored drugs issued by the National Health and Medical Commission, they did not include proprietary Chinese medicines
.
And which major varieties will be included in the catalogue in the end? What kind of market changes will usher in? There is still time to be revealed
.
Secondly, there was a new update on the volume procurement dynamics in September, and the special centralized procurement of insulin and Chinese patent medicines continued to advance
.
On the day of Teacher’s Day, the Office of Joint Procurement of National Organizations of Drugs released the sixth batch of public information on companies and products that state-organized centralized drug procurement (insulin special)
.
The reporting was started a week later
.
In the future, the domestic insulin market is very likely to undergo drastic changes
.
Let's talk about the centralized procurement of Chinese patent medicines
.
On September 25th, Hubei issued an announcement on the centralized procurement of the Inter-Provincial Volume Procurement Alliance of Chinese Patent Medicines
.
The alliance includes 19 provinces, and the overall plan is Group A and Group B + double envelope + belt measurement mode
.
According to the announcement, the 74 Chinese patent medicines involved in this centralized procurement are all varieties with large clinical usage and high purchase amount
.
Hubei stated that the rate of decrease will be the most important principle for the selection in this centralized procurement
.
However, the corporate side does not seem to be nervous, and said that it does not care about the pressure of price cuts
.
This month’s heavy pharmaceutical policies include: the start of the new round of centralized procurement in Anhui, the intensive transfer of local medical insurance supplements, the inclusion of 5 outpatient chronic diseases into the scope of the inter-provincial settlement of treatment costs, the results of the national procurement of artificial joints, Henan New “retaliatory” regulations have been issued on the drug bidding website, and the State Council has issued a document requesting coordination of various levels of procurement work.
.
.